AIM
AVEO

Alambic Investment Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Alambic Investment Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,291
Closed -$95K – 502
2018
Q1 		$95K Sell
3,291
-130
-4% -$3.8K 0.01% 439
2017
Q4 		$95K Hold
3,421
– – 0.01% 436
2017
Q3 		$125K Buy
+3,421
New +$106K 0.01% 464

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alambic Investment Management's AVEO Position: Q2 2018 in Review

Alambic Investment Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2018, closing a stake of 3,291 shares — an estimated $95K sold.

Alambic Investment Management first reported a position in AVEO in Q3 2017 and held it in 3 quarters. The position peaked at $125K in Q3 2017. 94 funds tracked by Wall St. Rank hold AVEO as of Q2 2018.

  • Alambic Investment Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Alambic Investment Management sold 3,291 AVEO Pharmaceuticals, Inc. shares in Q2 2018, an estimated $95K.
  • Alambic Investment Management first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and held it in 3 quarters.
  • Alambic Investment Management's AVEO Pharmaceuticals, Inc. position peaked at $125K in Q3 2017.
  • 94 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2018.

Based on Alambic Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.